Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease : Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
Date
2017-11-28
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
Wilcock, G K, Gauthier, S, Frisoni, G B, Jia, J, Hardlund, J H, Moebius, H J, Bentham, P, Kook, K A, Schelter, B O, Wischik, D J, Davis, C S, Staff, R T, Vuksanovic, V, Ahearn, T, Bracoud, L, Shamsi, K, Marek, K, Seibyl, J, Riedel, G, Storey, J M D, Harrington, C R & Wischik, C M 2017, 'Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease : Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial', Journal of Alzheimer's Disease, vol. 61, no. 1, pp. 435-457. https://doi.org/10.3233/JAD-170560